These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 38836372)

  • 1. Efficacy of astragalus combined with renin-angiotensin-aldosterone system blockers in the treatment of stage III diabetic nephropathy: a systematic review and meta-analysis.
    Lin YQ; Yu F; Chen HJ; Deng YR; Lin J; Xu Y; Zheng X; Zhang JW; Liu JF
    Ren Fail; 2024 Dec; 46(2):2359033. PubMed ID: 38836372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of astragalus injection combined with Western medicine in the treatment of early diabetic nephropathy: A protocol for systematic review and meta-analysis.
    Li G; Ai B; Zhang W; Feng X; Jiang M
    Medicine (Baltimore); 2021 Mar; 100(12):e25096. PubMed ID: 33761672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of tripterygium glycosides combined with ARB on diabetic nephropathy: a meta-analysis.
    Wu X; Huang Y; Zhang Y; He C; Zhao Y; Wang L; Gao J
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33057690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yuquan pill enhance the effect of Western medicine in treatment diabetic nephropathy: A protocol for systematic review and meta-analysis.
    Liu L; Zhang Y; Zhu Z; Yu Z; Bao P; Nan Z
    Medicine (Baltimore); 2021 Oct; 100(42):e27555. PubMed ID: 34678893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of renin-angiotensin system blockers on renal and cardiovascular outcomes in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials.
    Liu X; Ma L; Li Z
    J Endocrinol Invest; 2020 Jul; 43(7):959-972. PubMed ID: 31939197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xuebijing injection combined with alprostadil in the treatment of diabetic nephropathy: A PRISMA-compliant systematic review and meta-analysis.
    Hao N; Liu Y; Guo L; Li W; Zhao P
    Medicine (Baltimore); 2024 Jun; 103(24):e32095. PubMed ID: 38875385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
    Zain M; Awan FR
    Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis.
    Tian ML; Shen Y; Sun ZL; Zha Y
    Int Urol Nephrol; 2015 May; 47(5):815-22. PubMed ID: 25862237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
    Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y
    Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
    Du YH; Guan CJ; Li LY; Gan P
    Ann Palliat Med; 2022 Mar; 11(3):1093-1101. PubMed ID: 35365039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of astragalus injection combined with ACEI/ARB in the treatment of diabetic kidney disease: Protocol for a systematic review and meta-analysis.
    Zhu Z; Zhang Q; Liu L; Bao P; Liu S; Song C; Yang W; Nan Z
    Medicine (Baltimore); 2022 Dec; 101(49):e31490. PubMed ID: 36626537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combined angiotensin II receptor blocker with tripterygium glycosides on diabetic nephropathy: A protocol for meta-analysis.
    Ma CE; Yu P; Wei W; Chen XQ
    Medicine (Baltimore); 2021 Jun; 100(22):e25991. PubMed ID: 34087843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of seven Chinese patent medicines for early diabetic kidney disease: A Bayesian network meta-analysis.
    Zhao J; Ai J; Mo C; Shi W; Meng L
    Complement Ther Med; 2022 Aug; 67():102831. PubMed ID: 35398481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual Blockade of the Renin-angiotensin-aldosterone System in Type 2 Diabetic Kidney Disease.
    Feng YH; Fu P
    Chin Med J (Engl); 2016 Jan; 129(1):81-7. PubMed ID: 26712437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'Huang Qi Elixir' for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial.
    Tu X; Liu F; Jordan JB; Ye XF; Fu P; Wang F; Zhong S
    Trials; 2013 Jul; 14():223. PubMed ID: 23866835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
    Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
    Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.